# Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

> **NCT03980769** · PHASE2 · RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder

## Interventions

- **DRUG:** Thiotepa
- **DRUG:** Treosulfan
- **DRUG:** Fludarabine Phosphate
- **BIOLOGICAL:** Rabbit Anti-Thymocyte Globulin
- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT03980769
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-05
- **Primary completion:** 2028-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03980769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03980769, "Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03980769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*